IL1RL1 and polyposis: The multivariate analysis showed that the independent variables associated with a satisfactory response for reduction in exacerbations after 12 months of omalizumab treatment were the absence of polyposis (OR = 4.22; 95% CI = 0.95–19.63), the IL1RL1 rs17026974-AG genotype (OR = 19.07; 95% CI = 1.27–547; AG vs. AA), and the IL1RL1 rs17026974-GG genotype (OR = 16.76; 95% CI = 1.22–438.76; GG vs. AA) (Table 3).